The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, Pedersen TR, Keech AC, Roselli C, Lubitz SA, Ellinor PT, O'Donoghue ML, Giugliano RP, Ruff CT, Sabatine MS.
Marston NA, et al. Among authors: ruff ct.
Circulation. 2020 May 19;141(20):1600-1607. doi: 10.1161/CIRCULATIONAHA.120.046397. Epub 2020 Mar 29.
Circulation. 2020.
PMID: 32223429
Free PMC article.